Insider · CIK 0002048879
Amnon Peled
Files at SLXN (Silexion Therapeutics Corp). First filing -, latest -.
In brief
Amnon Peled files SEC Form 4 as director at SLXN (Silexion Therapeutics Corp). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Amnon Peled has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 20, 2026 | SLXN Silexion Therapeutics Corp | AGrant or award Ordinary Shares | +7,576 | $0.00 | $0 | 8,237 | Feb 23, 2026 |
| Feb 20, 2026 | SLXN Silexion Therapeutics Corp | AGrant or award Stock Option (right to buy Ordinary Shares)derivative | +8,904 | $0.00 | $0 | 8,904 | Feb 23, 2026 |
| Feb 9, 2025 | SLXN Silexion Therapeutics Corp | AGrant or award Ordinary Shares | +661 | $0.00 | $0 | 661 | Dec 31, 2025 |
| Feb 9, 2025 | SLXN Silexion Therapeutics Corp | AGrant or award Stock Option (right to buy Ordinary Shares)derivative | +780 | $0.00 | $0 | 780 | Dec 31, 2025 |
Questions about Amnon Peled
Answered from the filings on this page, as of the latest one.
Is Amnon Peled buying or selling?
Amnon Peled has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Amnon Peled's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Amnon Peled has 0.
Where does Amnon Peled file Form 4?
Amnon Peled has filed Form 4 at SLXN (Silexion Therapeutics Corp). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.